Marea Therapeutics
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
MAR-202 is a randomized, multicenter, double-blind, placebo-controlled dose-range finding study. After screening, participants who meet all eligibility criteria will be randomized to 1 of 3 active MAR002 regimens or matching placebo in a 3:1 ratio for a 10-week Treatment Period. During the Treatment Period, study drug (MAR002 or matching placebo) will be administered at study visits every 2 weeks (Q2W; Days 1, 15, 29, 43, and 57) followed then by a Follow-up Period before the End of Study (EOS) Visit on Week 16. This study will aim to enroll a total of approximately 72 participants with acro…
Inclusion Criteria: 1. Willing to provide written informed consent and comply with study procedures as specified in this protocol and comply with study treatment. 2. Age 18 to 75 years (inclusive) at screening with active acromegaly confirmed by an endocrinologist specialized in the care of pituitary patients. At a minimum, there must be documentation of a pituitary tumor (e.g., imaging evidence of a pituitary tumor by magnetic resonance imaging \[MRI\]/computerized tomography \[CT\] or histopathologic evidence of pituitary adenoma following pituitary surgery) and an elevated IGF-1 in the pas…
Subcutaneous injection
Subcutaneous injection
Arctuva estimate
Verify or correct the compensation shown for this listing.